Preclinical approaches to evaluate Uncaria tomentosa bark extract loaded FDOFs using osteoarthritis models

Osteoarthritis (OA) is one of the biggest global health issues, affecting two thirds of the population and cannot be fully treated to return normal function or relieve joint discomfort. Oral fast-dissolving films offer a high medication loading capacity, targeted distribution, and increasing bioavailability. The current research explores the in vitro and in vivo efficacy of oral fast-dissolving film formulations containing Uncaria tomentosa bark extract. A three-dimensional osteoarthritis (OA) model was created for in vitro assessment using first passage chrondrocytes cultured in a 1:1:3 ratio on trypsin-EDTA medium. C20A4 chondrocytes were cultured on agarose gel at 25± 5 °C in a phosphate buffer solution to create the OA agarose model. One milliliter of RPMI-1640 (10 % FBS) was used for chrondrocyte cultivation. On the third day of incubation, a 20 % (IL-1β) solution was applied, and the media was periodically changed. On the fifth day of incubation, the treated cell line received 5 μL of 0.5 % MTT reagent, and absorbance was examined at 570 nm. The effects of FDOFs on the cell lines were examined for 7, 13, 27, and 35 days (IL-1β, F5, F13 treated IL-1β injected types and Control). As a control, chondrocytes in agarose constructs were solely grown in RPMI-FBS medium without IL-1β. The arthritic effect of improved FDOFs, i.e., F5, was investigated using the GAG, HYP, and DNA quantitation assays in conjunction with a DNA content assay. Monoiodoacetate (MIA) produced arthritis models are well-established for understanding weight bearing and reaction to tactile stimuli in invivo research. Seven-week-old male wistar rats were used in the invivo technique, with celecoxib serving as the positive control and MIA as the negative control. Estimates of osteoarthritic potential were made based on the evaluation of knee thickness and discomfort. The study's findings demonstrated the effectiveness of the F5 formulation on OA models, which need for a clinical evaluation in human beings.